- Home
- OBT vs CTNM Comparison
OBT vs CTNM Comparison
Compare OBT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBT
- CTNM
- Stock Information
- Founded
- OBT 1892
- CTNM 2009
- Country
- OBT United States
- CTNM United States
- Employees
- OBT N/A
- CTNM N/A
- Industry
- OBT Major Banks
- CTNM
- Sector
- OBT Finance
- CTNM
- Exchange
- OBT Nasdaq
- CTNM Nasdaq
- Market Cap
- OBT 368.1M
- CTNM 328.1M
- IPO Year
- OBT N/A
- CTNM 2024
- Fundamental
- Price
- OBT $24.63
- CTNM $11.12
- Analyst Decision
- OBT Buy
- CTNM Strong Buy
- Analyst Count
- OBT 1
- CTNM 5
- Target Price
- OBT $29.00
- CTNM $22.20
- AVG Volume (30 Days)
- OBT 23.7K
- CTNM 112.3K
- Earning Date
- OBT 10-24-2025
- CTNM 11-05-2025
- Dividend Yield
- OBT 2.13%
- CTNM N/A
- EPS Growth
- OBT N/A
- CTNM N/A
- EPS
- OBT 2.57
- CTNM N/A
- Revenue
- OBT $105,510,000.00
- CTNM N/A
- Revenue This Year
- OBT $18.34
- CTNM N/A
- Revenue Next Year
- OBT $6.14
- CTNM N/A
- P/E Ratio
- OBT $9.52
- CTNM N/A
- Revenue Growth
- OBT 2.48
- CTNM N/A
- 52 Week Low
- OBT $20.97
- CTNM $3.35
- 52 Week High
- OBT $33.06
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- OBT 47.53
- CTNM 48.97
- Support Level
- OBT $23.27
- CTNM $10.16
- Resistance Level
- OBT $24.75
- CTNM $12.87
- Average True Range (ATR)
- OBT 0.61
- CTNM 0.86
- MACD
- OBT 0.04
- CTNM -0.19
- Stochastic Oscillator
- OBT 69.39
- CTNM 35.42
About OBT Orange County Bancorp Inc.
Orange County Bancorp Inc provides banking services. Its services include personal banking services such as personal loans, personal savings, business loans, business savings, and Internet banking among others. The company provides commercial and consumer banking services to individuals, small businesses, and local municipal governments as well as trust and investment services through the Bank and HVIA. Its segment includes banking and wealth management. The company generates maximum revenue from the banking segment.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.